ReviewWorld journal of gastroenterology2016
Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 223 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
223 citing papers in PubMed, 4 syntheses or guidelines pooled it, 412 citations in OpenAlex.
- Racial disparities in colorectal cancer clinicopathological and molecular tumor characteristics: a systematic review.Cancer causes & control : CCC · 2024Pooled it
- The histological and molecular characteristics of early-onset colorectal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- The Molecular Associations of Signet-Ring Cell Carcinoma in Colorectum: Meta-Analysis and System Review.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Biomarker concordance between primary colorectal cancer and its metastases.EBioMedicine · 2019Pooled it
- A Retrospective Study from a Single Center to Identify Hematological Factors that Distinguish Between Patients with Colorectal Carcinoma and Colorectal Adenoma.Medical science monitor : international medical journal of experimental and clinical research · 2022Trial
- Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.Cancer chemotherapy and pharmacology · 2022Trial
- Radiomic analysis for predicting prognosis of colorectal cancer from preoperativeJournal of translational medicine · 2022Trial
- Trial
- Metabolic reprogramming in colorectal cancer: Mechanisms and therapeutic insights.Genes & diseases · 2027Review
- Article
- Assessment of Outcome in 198 Patients With Mucinous Appendiceal Adenocarcinoma and Peritoneal Metastases Over 25 Years.Journal of surgical oncology · 2026Review
- Prognostic value of lncRNA DARS-AS1 in colorectal cancer and its regulatory effect on tumor progression.BMC gastroenterology · 2026Article
- M2 macrophage associated genes shape prognosis and tumor progression in human colorectal cancer.iScience · 2026Article
- The Mechanistic Crosstalk between Probiotics, ncRNAs, and Autophagy: Implications for Colorectal Cancer Precision Medicine.Expert reviews in molecular medicine · 2026Review
- Machine Learning-Assisted Plasma Metabolomics Identifies a Five-Metabolite Panel for Colorectal Cancer Detection.ACS omega · 2026Article
- A multimodal radiomics model to predict disease-free survival in resected non-small cell lung cancer: integrating clinicopathology, dual-energy CT, and deep learning features.Journal of thoracic disease · 2026Article
- Small-nucleolar RNA host gene3 (SNHG3) and leukemia-associated non-coding IGF1R activator RNA 1 (LUNAR1) correlated with CRC patients' clinical features: a step-toward ncRNA-precision.Scientific reports · 2026Article
- Elevated PXDC1 expression linked to poor prognosis and abnormalities in PD-L1 regulation and NK cell function in colorectal cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Blood Biomarkers of Glucose Metabolism and Liver Function Modestly Improve Prediction of High-Risk Adenomas.Gastro hep advances · 2026Article
- Interpretable Machine Learning Models Based on Blood Cell-Derived Inflammatory Indices for Identifying Colorectal Neoplasia: A Retrospective Study.Journal of inflammation research · 2026Article
163 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the second most commonly diagnosed cancer among females and third among males worldwide. It also contributes significantly to cancer-related deaths, despite the continuous progress in diagnostic and therapeutic methods. Biomarkers currently play an important role in the detection and treatment of patients with colorectal cancer. Risk stratification for screening might be augmented by finding new biomarkers which alone or as a complement of existing tests might recognize either the predisposition or early stage of the disease. Biomarkers have also the potential to change diagnostic and treatment algorithms by selecting the proper chemotherapeutic drugs across a broad spectrum of patients. There are attempts to personalise chemotherapy based on presence or absence of specific biomarkers. In this review, we update review published last year and describe our understanding of tumour markers and biomarkers role in CRC screening, diagnosis, treatment and follow-up. Goal of future research is to identify those biomarkers that could allow a non-invasive and cost-effective diagnosis, as well as to recognise the best prognostic panel and define the predictive biomarkers for available treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.